Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Tango Therapeutics Inc. — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $26.6 (market cap $70.90M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 52.8× KraneShares Electric Vehicles and Future Mobility's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 48 Days and Tango Therapeutics Inc. for 0 Days on average.
| KARS | TNGX | |
|---|---|---|
Market Cap | $70.90M | $3.74B |
Volume | 2,312 | 3,438,781 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $32.90 |
52-Week Low | $26.72 | $7.50 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS stock trades at $27.18, down 0.88% on the day with a bearish technical signal. The stock faces resistance at $29 and support at $28, with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights challenges in the US electric vehicle market, which may impact automotive sector performance.
The outlook remains cautious given technical weakness and sector headwinds. Investment opportunity depends on company-specific fundamentals currently unavailable, while risks include EV market softness and regulatory uncertainty surrounding Chinese competition in the automotive industry.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
